Narrative review links gut microbial metabolites to colorectal cancer mechanisms

Photo by CDC / Unsplash

Frontiers in Medicine Published May 28, 2026 Medically reviewed May 28, 2026 DOI ↗ By Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

Key Takeaway

Consider gut microbial metabolites as mechanistic drivers of colorectal cancer with potential for precise treatment targeting.

This narrative review explores the dual role of gut microbial metabolites in the context of colorectal cancer. The scope of the article focuses on mechanistic pathways rather than clinical trial data. The authors describe how certain metabolites may strengthen the gut barrier and reduce inflammation to block abnormal cell growth and trigger apoptosis. Conversely, other metabolites are described as releasing inflammatory cytokines, damaging DNA, and driving uncontrolled proliferation.

The authors highlight several key limitations inherent to this field of study. These include the instability of metabolites, individual variation in host-microbe interactions, and the absence of biomarkers for patient selection. Because these factors vary significantly between individuals, the review does not provide pooled effect sizes or absolute numbers for clinical application.

The practice relevance identified by the authors is that targeting the gut microbiota-metabolite axis offers a promising path to more precise and effective treatments. However, clinicians should interpret these mechanistic insights with caution given the noted gaps in biomarker availability and the lack of reported adverse events or specific outcome data in this narrative synthesis.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedMay 2026

View Original Abstract ↓

A substantial body of evidence has elucidated the critical role of gut microbiota in the development and progression of colorectal cancer (CRC). Gut dysbiosis, defined as the disruption of microbiome homeostasis, has been implicated in the pathogenesis of various diseases, including CRC, Parkinson’s disease, and autoimmune liver disorders. In recent years, research has increasingly focused on microbial metabolites, with numerous studies confirming their association with CRC. This review systematically elucidates the dual roles of microbial metabolites in the initiation and progression of CRC: they can suppress tumors by strengthening the gut barrier, reducing inflammation, blocking abnormal cell growth, and triggering apoptosis; yet under dysbiotic conditions-like chronic inflammation or epithelial injury-they may promote cancer by releasing inflammatory cytokines, damaging DNA, and driving uncontrolled proliferation. We summarize key findings on these metabolites’ functions in CRC, highlight emerging metabolite-targeted therapies, and identify major hurdles to clinical translation: metabolite instability, individual variation in host-microbe interactions, and absent biomarkers for patient selection. Because the gut microbiota-metabolite axis is central to CRC biology, targeting it rationally offers a promising path to more precise and effective treatments. Ultimately, gut metabolites are not just disease indicators-they are actionable therapeutic targets.